Share Price and Basic Stock Data
Last Updated: January 22, 2026, 7:48 pm
| PEG Ratio | 17.22 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Mankind Pharma Ltd, a prominent player in the pharmaceuticals industry, reported a market capitalization of ₹86,652 Cr and a share price of ₹2,099. The company’s sales for the fiscal year ending March 2025 stood at ₹9,498 Cr, reflecting a steady growth trajectory from ₹8,127 Cr in March 2023. Quarterly sales figures also showed resilience, with the latest reported sales of ₹2,544 Cr in September 2024, which is an increase from ₹2,092 Cr in June 2023. This consistent upward trend underscores Mankind’s robust operational capabilities amidst a competitive landscape. The company’s operating profit margin (OPM) stood at 27% for the trailing twelve months, indicating effective cost management and pricing strategies. Additionally, the company’s reserves reached ₹15,469 Cr, providing a solid foundation for future growth and investment opportunities. Overall, Mankind’s revenue trends demonstrate its ability to adapt and thrive within the dynamic pharmaceutical sector.
Profitability and Efficiency Metrics
Mankind Pharma’s profitability metrics reflect a healthy financial performance, with a net profit of ₹1,666 Cr and a return on equity (ROE) of 13.9%. The company’s operating profit margin (OPM) of 27% aligns favorably with industry standards, suggesting effective operational efficiency. The net profit margin stood at 16.37% for the fiscal year ending March 2025, indicating solid profitability relative to sales. Furthermore, the interest coverage ratio (ICR) of 8.28x highlights the company’s strong ability to meet its interest obligations, a crucial factor for financial stability. However, the cash conversion cycle (CCC) of 108 days raises concerns about working capital efficiency, as it indicates a longer duration for converting investments into cash flow. While Mankind has demonstrated robust profitability, managing its cash flow efficiently will be essential in sustaining its growth momentum in the future.
Balance Sheet Strength and Financial Ratios
Mankind Pharma’s balance sheet exhibits a mixture of strengths and potential vulnerabilities. The total liabilities reported at ₹24,862 Cr against total assets of ₹24,862 Cr indicate a balanced structure, although the borrowings of ₹7,248 Cr could pose a risk if not managed effectively. The debt-to-equity ratio stood at 0.59, suggesting a moderate level of leverage. The company’s book value per share increased to ₹347.37, reflecting a solid equity base. However, the price-to-book value (P/BV) ratio of 6.98x indicates that the stock is trading at a premium relative to its book value, which may lead to valuation concerns among investors. Furthermore, the return on capital employed (ROCE) of 15% shows a declining trend from previous years, warranting attention to ensure capital is used effectively. Overall, while Mankind’s balance sheet is generally robust, careful monitoring of its leverage and capital efficiency will be crucial for long-term sustainability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Mankind Pharma reveals a strong promoter presence, with promoters holding 72.67% of the company as of September 2025. This significant stake by insiders typically signals confidence in the company’s future prospects. Institutional investors also have a notable presence, with foreign institutional investors (FIIs) holding 12.83% and domestic institutional investors (DIIs) at 11.91%. However, the public shareholding has declined to 2.57%, suggesting limited retail investor participation. The number of shareholders stood at 1,70,347, indicating a growing interest in the company, albeit with a shrinking public float. This concentration of ownership could lead to volatility in stock performance, particularly if there are significant changes in the shareholding structure. Overall, the current shareholding dynamics reflect a solid foundation of institutional support, which could enhance investor confidence in Mankind’s strategic direction.
Outlook, Risks, and Final Insight
Looking ahead, Mankind Pharma’s outlook appears promising, driven by its strong sales growth and solid profitability metrics. However, the company faces several risks, including its extended cash conversion cycle, which may impact liquidity. Additionally, the reliance on a concentrated shareholder base could lead to stock price volatility. The company’s ability to navigate regulatory challenges in the pharmaceutical sector is another critical factor that could influence its future performance. To mitigate these risks, Mankind may need to enhance its cash flow management and diversify its investor base. Given its current strengths, such as robust sales growth and a solid balance sheet, Mankind Pharma is well-positioned to capitalize on growth opportunities in the pharmaceutical market, provided it addresses the highlighted risks effectively. Overall, the company’s strategic initiatives and operational efficiency will play a pivotal role in determining its long-term success and market position.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 123 Cr. | 98.0 | 203/84.3 | 27.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,696 Cr. | 340 | 479/192 | 76.5 | 24.3 | 0.20 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.3 Cr. | 43.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 61.0 Cr. | 41.6 | 42.0/17.0 | 145 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,739.31 Cr | 1,099.94 | 48.35 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,258 | 1,936 | 1,872 | 2,092 | 2,260 | 2,209 | 2,007 | 2,413 | 2,544 | 2,414 | 2,127 | 2,541 | 2,609 |
| Expenses | 1,735 | 1,563 | 1,491 | 1,594 | 1,662 | 1,636 | 1,482 | 1,837 | 1,781 | 1,668 | 1,650 | 1,868 | 1,916 |
| Operating Profit | 522 | 374 | 381 | 498 | 598 | 573 | 526 | 576 | 763 | 746 | 477 | 673 | 693 |
| OPM % | 23% | 19% | 20% | 24% | 26% | 26% | 26% | 24% | 30% | 31% | 22% | 26% | 27% |
| Other Income | 69 | 32 | 42 | 87 | 84 | 92 | 109 | 125 | 139 | 70 | 219 | 64 | 78 |
| Interest | 8 | 9 | 1 | 2 | 4 | 4 | 4 | 7 | 3 | 200 | 162 | 147 | 147 |
| Depreciation | 66 | 71 | 67 | 69 | 77 | 90 | 87 | 91 | 90 | 91 | 105 | 97 | 99 |
| Profit before tax | 517 | 326 | 355 | 514 | 601 | 571 | 543 | 603 | 810 | 525 | 429 | 494 | 525 |
| Tax % | 19% | 24% | 21% | 20% | 21% | 15% | 14% | 16% | 20% | 22% | 11% | 16% | 13% |
| Net Profit | 420 | 249 | 281 | 409 | 473 | 487 | 468 | 506 | 645 | 412 | 382 | 413 | 459 |
| EPS in Rs | 10.49 | 6.21 | 7.01 | 10.22 | 11.80 | 12.16 | 11.68 | 12.62 | 16.11 | 9.99 | 9.27 | 10.00 | 11.12 |
Last Updated: December 27, 2025, 8:40 pm
Below is a detailed analysis of the quarterly data for Mankind Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 2,609.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,541.00 Cr. (Jun 2025) to 2,609.00 Cr., marking an increase of 68.00 Cr..
- For Expenses, as of Sep 2025, the value is 1,916.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,868.00 Cr. (Jun 2025) to 1,916.00 Cr., marking an increase of 48.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 693.00 Cr.. The value appears strong and on an upward trend. It has increased from 673.00 Cr. (Jun 2025) to 693.00 Cr., marking an increase of 20.00 Cr..
- For OPM %, as of Sep 2025, the value is 27.00%. The value appears strong and on an upward trend. It has increased from 26.00% (Jun 2025) to 27.00%, marking an increase of 1.00%.
- For Other Income, as of Sep 2025, the value is 78.00 Cr.. The value appears strong and on an upward trend. It has increased from 64.00 Cr. (Jun 2025) to 78.00 Cr., marking an increase of 14.00 Cr..
- For Interest, as of Sep 2025, the value is 147.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 147.00 Cr..
- For Depreciation, as of Sep 2025, the value is 99.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 97.00 Cr. (Jun 2025) to 99.00 Cr., marking an increase of 2.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 525.00 Cr.. The value appears strong and on an upward trend. It has increased from 494.00 Cr. (Jun 2025) to 525.00 Cr., marking an increase of 31.00 Cr..
- For Tax %, as of Sep 2025, the value is 13.00%. The value appears to be improving (decreasing) as expected. It has decreased from 16.00% (Jun 2025) to 13.00%, marking a decrease of 3.00%.
- For Net Profit, as of Sep 2025, the value is 459.00 Cr.. The value appears strong and on an upward trend. It has increased from 413.00 Cr. (Jun 2025) to 459.00 Cr., marking an increase of 46.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 11.12. The value appears strong and on an upward trend. It has increased from 10.00 (Jun 2025) to 11.12, marking an increase of 1.12.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:05 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,918 | 3,829 | 4,794 | 5,530 | 7,486 | 8,127 | 8,629 | 9,498 | 9,691 |
| Expenses | 3,141 | 3,124 | 3,550 | 4,151 | 5,644 | 6,429 | 6,358 | 6,930 | 7,102 |
| Operating Profit | 778 | 705 | 1,244 | 1,379 | 1,842 | 1,698 | 2,272 | 2,567 | 2,589 |
| OPM % | 20% | 18% | 26% | 25% | 25% | 21% | 26% | 27% | 27% |
| Other Income | 209 | 64 | 94 | 148 | 200 | 163 | 369 | 550 | 432 |
| Interest | 18 | 40 | 11 | 8 | 48 | 28 | 17 | 372 | 656 |
| Depreciation | 28 | 38 | 62 | 78 | 123 | 270 | 335 | 378 | 392 |
| Profit before tax | 941 | 691 | 1,265 | 1,440 | 1,871 | 1,563 | 2,289 | 2,367 | 1,972 |
| Tax % | 26% | 26% | 24% | 25% | 26% | 20% | 18% | 18% | |
| Net Profit | 694 | 514 | 958 | 1,084 | 1,389 | 1,248 | 1,876 | 1,945 | 1,666 |
| EPS in Rs | 17.33 | 12.83 | 23.92 | 27.07 | 34.68 | 31.16 | 46.84 | 47.15 | 40.38 |
| Dividend Payout % | 0% | 0% | 32% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -25.94% | 86.38% | 13.15% | 28.14% | -10.15% | 50.32% | 3.68% |
| Change in YoY Net Profit Growth (%) | 0.00% | 112.32% | -73.23% | 14.98% | -38.29% | 60.47% | -46.64% |
Mankind Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
Last Updated: September 5, 2025, 2:40 pm
Balance Sheet
Last Updated: December 4, 2025, 2:30 am
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 41 | 41 |
| Reserves | 2,957 | 3,025 | 3,611 | 4,694 | 6,500 | 7,744 | 9,663 | 14,599 | 15,469 |
| Borrowings | 360 | 190 | 3 | 101 | 688 | 5 | 24 | 7,254 | 7,248 |
| Other Liabilities | 652 | 596 | 877 | 1,045 | 1,710 | 1,583 | 1,790 | 1,934 | 2,104 |
| Total Liabilities | 4,009 | 3,851 | 4,531 | 5,880 | 8,939 | 9,371 | 11,516 | 23,828 | 24,862 |
| Fixed Assets | 534 | 778 | 945 | 987 | 2,927 | 3,142 | 3,552 | 3,471 | 3,393 |
| CWIP | 322 | 211 | 148 | 166 | 387 | 495 | 209 | 207 | 248 |
| Investments | 1,402 | 1,698 | 1,784 | 2,397 | 2,526 | 3,102 | 4,215 | 16,683 | 17,611 |
| Other Assets | 1,751 | 1,164 | 1,655 | 2,330 | 3,100 | 2,632 | 3,540 | 3,467 | 3,610 |
| Total Assets | 4,009 | 3,851 | 4,531 | 5,880 | 8,939 | 9,371 | 11,516 | 23,828 | 24,862 |
Below is a detailed analysis of the balance sheet data for Mankind Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 41.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 41.00 Cr..
- For Reserves, as of Sep 2025, the value is 15,469.00 Cr.. The value appears strong and on an upward trend. It has increased from 14,599.00 Cr. (Mar 2025) to 15,469.00 Cr., marking an increase of 870.00 Cr..
- For Borrowings, as of Sep 2025, the value is 7,248.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 7,254.00 Cr. (Mar 2025) to 7,248.00 Cr., marking a decrease of 6.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 2,104.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,934.00 Cr. (Mar 2025) to 2,104.00 Cr., marking an increase of 170.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 24,862.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 23,828.00 Cr. (Mar 2025) to 24,862.00 Cr., marking an increase of 1,034.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3,393.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,471.00 Cr. (Mar 2025) to 3,393.00 Cr., marking a decrease of 78.00 Cr..
- For CWIP, as of Sep 2025, the value is 248.00 Cr.. The value appears strong and on an upward trend. It has increased from 207.00 Cr. (Mar 2025) to 248.00 Cr., marking an increase of 41.00 Cr..
- For Investments, as of Sep 2025, the value is 17,611.00 Cr.. The value appears strong and on an upward trend. It has increased from 16,683.00 Cr. (Mar 2025) to 17,611.00 Cr., marking an increase of 928.00 Cr..
- For Other Assets, as of Sep 2025, the value is 3,610.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,467.00 Cr. (Mar 2025) to 3,610.00 Cr., marking an increase of 143.00 Cr..
- For Total Assets, as of Sep 2025, the value is 24,862.00 Cr.. The value appears strong and on an upward trend. It has increased from 23,828.00 Cr. (Mar 2025) to 24,862.00 Cr., marking an increase of 1,034.00 Cr..
Notably, the Reserves (15,469.00 Cr.) exceed the Borrowings (7,248.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 418.00 | 515.00 | -2.00 | -100.00 | -687.00 | -4.00 | -22.00 | -5.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 23 | 13 | 32 | 24 | 23 | 22 | 33 | 34 |
| Inventory Days | 120 | 126 | 124 | 169 | 183 | 132 | 160 | 153 |
| Days Payable | 115 | 101 | 113 | 122 | 133 | 103 | 75 | 79 |
| Cash Conversion Cycle | 27 | 38 | 43 | 72 | 73 | 52 | 118 | 108 |
| Working Capital Days | 95 | 44 | 41 | 42 | 26 | 40 | 55 | -48 |
| ROCE % | 22% | 36% | 33% | 30% | 21% | 24% | 15% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Large Cap Fund | 4,072,930 | 1.65 | 916.82 | N/A | N/A | N/A |
| HDFC Large Cap Fund | 2,664,492 | 1.48 | 599.78 | 2,571,369 | 2025-12-15 06:13:35 | 3.62% |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 1,444,988 | 5.04 | 325.27 | N/A | N/A | N/A |
| Axis ELSS Tax Saver Fund | 1,330,911 | 0.85 | 299.59 | 1,961,633 | 2025-10-16 16:06:35 | -32.15% |
| SBI Contra Fund | 1,328,039 | 0.6 | 298.94 | N/A | N/A | N/A |
| Aditya Birla Sun Life Flexi Cap Fund | 1,325,544 | 1.2 | 298.38 | 1,310,000 | 2025-12-15 08:42:29 | 1.19% |
| Nippon India Growth Mid Cap Fund | 1,279,034 | 0.68 | 287.91 | N/A | N/A | N/A |
| Nippon India Large Cap Fund | 1,278,370 | 0.57 | 287.76 | N/A | N/A | N/A |
| Axis Flexi Cap Fund | 1,076,417 | 1.83 | 242.3 | N/A | N/A | N/A |
| Axis Focused Fund | 1,037,596 | 1.88 | 233.56 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 49.28 | 47.75 | 32.00 | 35.78 | 31.59 |
| Diluted EPS (Rs.) | 49.20 | 47.68 | 32.00 | 35.78 | 31.59 |
| Cash EPS (Rs.) | 63.50 | 58.03 | 40.52 | 40.07 | 34.96 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 347.37 | 239.04 | 190.30 | 157.68 | 121.39 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 347.37 | 239.04 | 190.30 | 157.68 | 121.39 |
| Revenue From Operations / Share (Rs.) | 295.87 | 257.99 | 218.41 | 194.25 | 155.13 |
| PBDIT / Share (Rs.) | 86.15 | 70.29 | 50.66 | 54.55 | 45.41 |
| PBIT / Share (Rs.) | 71.10 | 60.35 | 42.52 | 50.39 | 42.44 |
| PBT / Share (Rs.) | 60.69 | 59.52 | 41.41 | 48.93 | 41.94 |
| Net Profit / Share (Rs.) | 48.45 | 48.09 | 32.38 | 35.91 | 31.99 |
| NP After MI And SOA / Share (Rs.) | 48.25 | 47.75 | 32.00 | 35.78 | 31.59 |
| PBDIT Margin (%) | 29.11 | 27.24 | 23.19 | 28.08 | 29.27 |
| PBIT Margin (%) | 24.03 | 23.39 | 19.46 | 25.94 | 27.35 |
| PBT Margin (%) | 20.51 | 23.06 | 18.95 | 25.18 | 27.03 |
| Net Profit Margin (%) | 16.37 | 18.64 | 14.82 | 18.48 | 20.61 |
| NP After MI And SOA Margin (%) | 16.30 | 18.50 | 14.65 | 18.42 | 20.36 |
| Return on Networth / Equity (%) | 13.89 | 20.43 | 17.24 | 23.28 | 26.79 |
| Return on Capital Employeed (%) | 13.27 | 24.56 | 21.69 | 30.94 | 33.87 |
| Return On Assets (%) | 7.17 | 15.98 | 13.19 | 15.67 | 19.85 |
| Long Term Debt / Equity (X) | 0.38 | 0.00 | 0.00 | 0.01 | 0.01 |
| Total Debt / Equity (X) | 0.59 | 0.02 | 0.02 | 0.14 | 0.05 |
| Asset Turnover Ratio (%) | 0.61 | 0.95 | 0.87 | 0.98 | 1.01 |
| Current Ratio (X) | 1.23 | 3.10 | 2.32 | 1.68 | 2.89 |
| Quick Ratio (X) | 0.86 | 2.37 | 1.52 | 1.01 | 2.01 |
| Inventory Turnover Ratio (X) | 6.69 | 1.21 | 0.50 | 0.64 | 0.57 |
| Interest Coverage Ratio (X) | 8.28 | 83.98 | 45.63 | 37.29 | 90.29 |
| Interest Coverage Ratio (Post Tax) (X) | 5.64 | 58.45 | 30.17 | 25.54 | 64.60 |
| Enterprise Value (Cr.) | 108143.49 | 91239.85 | 0.00 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 8.86 | 8.83 | 0.00 | 0.00 | 0.00 |
| EV / EBITDA (X) | 30.42 | 32.40 | 0.00 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 8.19 | 8.90 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 6.98 | 9.83 | 0.00 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 8.19 | 8.90 | 0.00 | 0.00 | 0.00 |
| EarningsYield | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 |
After reviewing the key financial ratios for Mankind Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 49.28. This value is within the healthy range. It has increased from 47.75 (Mar 24) to 49.28, marking an increase of 1.53.
- For Diluted EPS (Rs.), as of Mar 25, the value is 49.20. This value is within the healthy range. It has increased from 47.68 (Mar 24) to 49.20, marking an increase of 1.52.
- For Cash EPS (Rs.), as of Mar 25, the value is 63.50. This value is within the healthy range. It has increased from 58.03 (Mar 24) to 63.50, marking an increase of 5.47.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 347.37. It has increased from 239.04 (Mar 24) to 347.37, marking an increase of 108.33.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 347.37. It has increased from 239.04 (Mar 24) to 347.37, marking an increase of 108.33.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 295.87. It has increased from 257.99 (Mar 24) to 295.87, marking an increase of 37.88.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 86.15. This value is within the healthy range. It has increased from 70.29 (Mar 24) to 86.15, marking an increase of 15.86.
- For PBIT / Share (Rs.), as of Mar 25, the value is 71.10. This value is within the healthy range. It has increased from 60.35 (Mar 24) to 71.10, marking an increase of 10.75.
- For PBT / Share (Rs.), as of Mar 25, the value is 60.69. This value is within the healthy range. It has increased from 59.52 (Mar 24) to 60.69, marking an increase of 1.17.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 48.45. This value is within the healthy range. It has increased from 48.09 (Mar 24) to 48.45, marking an increase of 0.36.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 48.25. This value is within the healthy range. It has increased from 47.75 (Mar 24) to 48.25, marking an increase of 0.50.
- For PBDIT Margin (%), as of Mar 25, the value is 29.11. This value is within the healthy range. It has increased from 27.24 (Mar 24) to 29.11, marking an increase of 1.87.
- For PBIT Margin (%), as of Mar 25, the value is 24.03. This value exceeds the healthy maximum of 20. It has increased from 23.39 (Mar 24) to 24.03, marking an increase of 0.64.
- For PBT Margin (%), as of Mar 25, the value is 20.51. This value is within the healthy range. It has decreased from 23.06 (Mar 24) to 20.51, marking a decrease of 2.55.
- For Net Profit Margin (%), as of Mar 25, the value is 16.37. This value exceeds the healthy maximum of 10. It has decreased from 18.64 (Mar 24) to 16.37, marking a decrease of 2.27.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.30. This value is within the healthy range. It has decreased from 18.50 (Mar 24) to 16.30, marking a decrease of 2.20.
- For Return on Networth / Equity (%), as of Mar 25, the value is 13.89. This value is below the healthy minimum of 15. It has decreased from 20.43 (Mar 24) to 13.89, marking a decrease of 6.54.
- For Return on Capital Employeed (%), as of Mar 25, the value is 13.27. This value is within the healthy range. It has decreased from 24.56 (Mar 24) to 13.27, marking a decrease of 11.29.
- For Return On Assets (%), as of Mar 25, the value is 7.17. This value is within the healthy range. It has decreased from 15.98 (Mar 24) to 7.17, marking a decrease of 8.81.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.38. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.38, marking an increase of 0.38.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.59. This value is within the healthy range. It has increased from 0.02 (Mar 24) to 0.59, marking an increase of 0.57.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.61. It has decreased from 0.95 (Mar 24) to 0.61, marking a decrease of 0.34.
- For Current Ratio (X), as of Mar 25, the value is 1.23. This value is below the healthy minimum of 1.5. It has decreased from 3.10 (Mar 24) to 1.23, marking a decrease of 1.87.
- For Quick Ratio (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 1. It has decreased from 2.37 (Mar 24) to 0.86, marking a decrease of 1.51.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.69. This value is within the healthy range. It has increased from 1.21 (Mar 24) to 6.69, marking an increase of 5.48.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.28. This value is within the healthy range. It has decreased from 83.98 (Mar 24) to 8.28, marking a decrease of 75.70.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.64. This value is within the healthy range. It has decreased from 58.45 (Mar 24) to 5.64, marking a decrease of 52.81.
- For Enterprise Value (Cr.), as of Mar 25, the value is 108,143.49. It has increased from 91,239.85 (Mar 24) to 108,143.49, marking an increase of 16,903.64.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.86. This value exceeds the healthy maximum of 3. It has increased from 8.83 (Mar 24) to 8.86, marking an increase of 0.03.
- For EV / EBITDA (X), as of Mar 25, the value is 30.42. This value exceeds the healthy maximum of 15. It has decreased from 32.40 (Mar 24) to 30.42, marking a decrease of 1.98.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.19. This value exceeds the healthy maximum of 3. It has decreased from 8.90 (Mar 24) to 8.19, marking a decrease of 0.71.
- For Price / BV (X), as of Mar 25, the value is 6.98. This value exceeds the healthy maximum of 3. It has decreased from 9.83 (Mar 24) to 6.98, marking a decrease of 2.85.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.19. This value exceeds the healthy maximum of 3. It has decreased from 8.90 (Mar 24) to 8.19, marking a decrease of 0.71.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Mankind Pharma Ltd:
- Net Profit Margin: 16.37%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 13.27% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 13.89% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.64
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.86
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 53.2 (Industry average Stock P/E: 48.35)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.59
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 16.37%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 208, Okhla Industrial Estate, Phase-III, New Delhi Delhi 110020 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ramesh Juneja | Chairman & Wholetime Director |
| Mr. Rajeev Juneja | Vice Chairman & Mng.Director |
| Ms. Sheetal Arora | Whole Time Director |
| Mr. Satish Kumar Sharma | Whole Time Director |
| Mr. Vivek Kalra | Independent Director |
| Mr. Tilokchand Punamchand Ostwal | Independent Director |
| Mr. Bharat Anand | Independent Director |
| Ms. Vijaya Sampath | Independent Director |
FAQ
What is the intrinsic value of Mankind Pharma Ltd?
Mankind Pharma Ltd's intrinsic value (as of 22 January 2026) is ₹2294.24 which is 6.86% higher the current market price of ₹2,147.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹88,598 Cr. market cap, FY2025-2026 high/low of ₹2,727/2,082, reserves of ₹15,469 Cr, and liabilities of ₹24,862 Cr.
What is the Market Cap of Mankind Pharma Ltd?
The Market Cap of Mankind Pharma Ltd is 88,598 Cr..
What is the current Stock Price of Mankind Pharma Ltd as on 22 January 2026?
The current stock price of Mankind Pharma Ltd as on 22 January 2026 is ₹2,147.
What is the High / Low of Mankind Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Mankind Pharma Ltd stocks is ₹2,727/2,082.
What is the Stock P/E of Mankind Pharma Ltd?
The Stock P/E of Mankind Pharma Ltd is 53.2.
What is the Book Value of Mankind Pharma Ltd?
The Book Value of Mankind Pharma Ltd is 376.
What is the Dividend Yield of Mankind Pharma Ltd?
The Dividend Yield of Mankind Pharma Ltd is 0.05 %.
What is the ROCE of Mankind Pharma Ltd?
The ROCE of Mankind Pharma Ltd is 15.0 %.
What is the ROE of Mankind Pharma Ltd?
The ROE of Mankind Pharma Ltd is 13.9 %.
What is the Face Value of Mankind Pharma Ltd?
The Face Value of Mankind Pharma Ltd is 1.00.